RT Journal Article
SR Electronic
T1 Favourable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.02.15.431291
DO 10.1101/2021.02.15.431291
A1 Claire T. Deakin
A1 Georgina H. Cornish
A1 Kevin W. Ng
A1 Nikhil Faulkner
A1 William Bolland
A1 Veera Panova
A1 Joshua Hope
A1 Annachiara Rosa
A1 Ruth Harvey
A1 Saira Hussain
A1 Christopher Earl
A1 Bethany R. Jebson
A1 Meredyth G.Ll. Wilkinson
A1 Lucy R. Marshall
A1 Kathryn O’Brien
A1 Elizabeth C. Rosser
A1 Anna Radziszewska
A1 Hannah Peckham
A1 Judith Heaney
A1 Hannah Rickman
A1 Stavroula Paraskevopoulou
A1 Catherine F. Houlihan
A1 Moira J. Spyer
A1 Steve J. Gamblin
A1 John McCauley
A1 Eleni Nastouli
A1 Peter Cherepanov
A1 Coziana Ciurtin
A1 Lucy R. Wedderburn
A1 George Kassiotis
YR 2021
UL http://biorxiv.org/content/early/2021/02/16/2021.02.15.431291.abstract
AB Differences in humoral immunity to coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), between children and adults remain unexplained and the impact of underlying immune dysfunction or suppression unknown. Here, we examined the antibody immune competence of children and adolescents with prevalent inflammatory rheumatic diseases, juvenile idiopathic arthritis (JIA), juvenile dermatomyositis (JDM) and juvenile systemic lupus erythematosus (JSLE), against the seasonal human coronavirus (HCoV)-OC43 that frequently infects this age group. Despite immune dysfunction and immunosuppressive treatment, JIA, JDM and JSLE patients mounted comparable or stronger responses than healthier peers, dominated by IgG antibodies to HCoV-OC43 spike, and harboured IgG antibodies that cross-reacted with SARS-CoV-2 spike. In contrast, responses to HCoV-OC43 and SARS-CoV-2 nucleoproteins exhibited delayed age-dependent class-switching and were not elevated in JIA, JDM and JSLE patients, arguing against increased exposure. Consequently, autoimmune rheumatic diseases and their treatment were associated with a favourable ratio of spike to nucleoprotein antibodies.Competing Interest StatementThe authors have declared no competing interest.